top of page
Home
Calvine Healthcare
Calvine Sustainables
Equity Research
Basilea
Blog
Contact
Â
Use tab to navigate through the menu items.
All Posts
Search
Brian White
Jun 8, 2023
Basilea - Cresemba exceeding expectations
Brian White
Apr 18, 2023
Ceftobiprole delay a minor frustration
Brian White
Mar 23, 2023
Cresemba continues to deliver
Andrew Keith
Mar 15, 2023
Basilea's future in anti-infectives
Brian White
Feb 7, 2023
Another Cresemba Pfizer milestone
Brian White
Jan 11, 2023
Basilea - a year of significant achievement
Brian White
Jan 9, 2023
CHF20m Astellas milestone
Brian White
Dec 23, 2022
Basilea - Cresemba approved in Japan
Andrew Keith
Nov 9, 2022
Basilea - Sustainable profitability
Brian White
Nov 2, 2022
Basilea - Another oncology programme partnered
Brian White
Oct 24, 2022
Basilea - Positive data at IDweek
Brian White
Sep 20, 2022
Basilea - Still capturing value from oncology
Brian White
Sep 8, 2022
Basilea - Focus on anti-infectives apparent
Brian White
Sep 7, 2022
Basilea - Dilution overhang removed
Brian White
Aug 16, 2022
Basilea - H1 results show continued commercial and strategic progress
Brian White
Jul 26, 2022
Diurnal Group - Trading update ahead of R&D Day
Brian White
Jun 28, 2022
Basilea - Positive Phase 3 results
Brian White
Jun 27, 2022
Basilea - New positioning apparent
Brian White
Jun 17, 2022
Basilea - New territory growth
Andrew Keith
Jun 7, 2022
Basilea - The prospects for anti-infectives
bottom of page
